Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Debt (2017 - 2023)

Sutro Biopharma's Total Debt history spans 7 years, with the latest figure at $4.1 million for Q4 2023.

  • For Q4 2023, Total Debt fell 75.04% year-over-year to $4.1 million; the TTM value through Dec 2023 reached $4.1 million, down 75.04%, while the annual FY2023 figure was $4.1 million, 75.04% down from the prior year.
  • Total Debt for Q4 2023 was $4.1 million at Sutro Biopharma, down from $7.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $25.3 million in Q1 2022 and bottomed at $4.1 million in Q4 2023.
  • The 5-year median for Total Debt is $20.8 million (2022), against an average of $18.1 million.
  • The largest annual shift saw Total Debt surged 148.53% in 2020 before it tumbled 75.04% in 2023.
  • A 5-year view of Total Debt shows it stood at $9.9 million in 2019, then soared by 148.53% to $24.5 million in 2020, then increased by 2.31% to $25.1 million in 2021, then tumbled by 35.21% to $16.3 million in 2022, then crashed by 75.04% to $4.1 million in 2023.
  • Per Business Quant, the three most recent readings for STRO's Total Debt are $4.1 million (Q4 2023), $7.1 million (Q3 2023), and $10.2 million (Q2 2023).